Back to Peptides
Fat LossLow Risk

AOD-9604

Also known as: Advanced Obesity Drug 9604, hGH Fragment 176-191

Half-life:
30–60 minutes

Administration Routes

subcutaneousoral
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

AOD-9604 is a synthetic fragment of the human growth hormone molecule, corresponding to amino acids 176–191 of the C-terminus. It is researched specifically for its lipolytic properties and is considered a lower-risk alternative to full growth hormone analogues for body composition research, given its apparent lack of effect on insulin sensitivity or IGF-1 levels.

Primary Research Areas

  • fat_loss

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Providers Offering AOD-9604